Walters GROUP, 10% Owner at Zentalis Pharmaceuticals, Inc. (ZNTL), bought 4,335,000 shares at $3.50 ($15.2M) on 2026-08-14, disclosed to the SEC on 2026-08-19.
The Walters Group executed a massive $15.17 million purchase of 4.335 million shares at $3.50, marking the largest insider trade in the company's history, signaling high conviction in the stock's recovery despite recent volatility.
The stock has sold off significantly recently, dropping 14.44% over the last 5 days and 26.65% over the last 30 days, though it remains up 131.13% over the past year and is currently trading 47.05% below its 52-week high of $6.94.
1) Upcoming DENALI dose selection for azenosertib in Cyclin E1-positive ovarian cancer (expected by April 2026); 2) FDA alignment on the Phase 3 ASPENOVA trial design (announced Feb 16, 2026); 3) The current insider buying cluster, as noted in recent news, coincides with clinical milestones and a sharp shift in sentiment.
The stock is highly volatile with a beta of 1.891 and currently trades at a forward P/E of -2.11, indicating the company is unprofitable, while short interest remains elevated at 9.73% of the float.
Negative factors outweigh the positive ones.